Item 5. OTHER INFORMATION
4K characters. Original on sec.gov ·
Item 5. OTHER INFORMATION
Trading Plans
During the three months ended June 30, 2023, none of our directors or officers informed us of the adoption or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408, except as described in the table below:
| Character of Trading Arrangement | ||||||||||||||||||||
| Name | Title | Adoption Date | Rule 10b5-1* | Non-Rule 10b5-1** | Total Shares to be Sold | Expiration Date**(1)** | ||||||||||||||
| Donald M. Abbey | Executive Vice President, Global Business Services, IT Quality and Regulatory Affairs | 5/5/2023 | X | 3,258 | 5/6/2024 | |||||||||||||||
| Steven R. Altman | Director | 5/30/2023 | X | 9,568 | 5/30/2025 | |||||||||||||||
| Bridgette P. Heller | Director | 6/13/2023 | X | 600 | 6/13/2024 | |||||||||||||||
| * Intended to satisfy the affirmative defense of Rule 10b5-1(c) | ||||||||||||||||||||
| ** Not intended to satisfy the affirmative defense of Rule 10b5-1(c) | ||||||||||||||||||||
| (1) Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the earlier to occur of (a) the completion of all purchases or sales or (b) the date listed in the table. |
Each new Rule 10b5-1 Plan that was adopted in the above table includes a representation from Ms. Heller, and Messrs. Abbey and Altman respectively, to the broker administering the plan that he or she was not in
possession of any material nonpublic information regarding Dexcom or the securities subject to the Rule 10b5-1 Plan at the time the Rule 10b5-1 Plan was entered into. A similar representation was made to Dexcom in connection with the adoption of the Rule 10b5-1 Plan under Dexcom’s insider trading policy. Those representations were made as of the Adoption Date set forth above, and speak only as of that date. In making those representations, there is no assurance with respect to any material nonpublic information of which the directors and officers was unaware, or with respect to any material nonpublic information acquired by the above directors and officers or Dexcom after the date of the representation.
Once executed, transactions under a Rule 10b5-1 Plan adopted during the period described above will be disclosed publicly through Form 4 and/or Form 144 filings with the SEC in accordance with applicable securities laws, rules, and regulations. Except as may be required by law, Dexcom does not undertake any obligation to update or report any modification, termination, or other activity under current or future Rule 10b5-1 plans that may be adopted by Ms. Heller, Messrs. Abbey and Altman, respectively, or other officers or directors of Dexcom.